Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07 2020 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity
inducement grants to two new employees consisting of 25,315
restricted stock units. The Compensation Committee of the Board of
Directors approved the grants with an effective date of August 3,
2020. The restricted stock units were granted as inducements
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the
shares vesting on each annual anniversary of the applicable vesting
commencement date, subject to the new employee’s continued service
relationship with the Company.
The restricted stock units are subject to the terms and
conditions of the Company's 2013 Equity Incentive Plan and a
restricted stock unit agreement covering the grant.
About Flexion Therapeutics Flexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, the most common form of
arthritis. The Company's core values are focus, ingenuity,
tenacity, transparency and fun.
Visit flexiontherapeutics.com.
Contact:Scott YoungVice President, Corporate
Communications & Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024